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3 
Summary 
 
 
People with diabetes mellitus account for up to 25% of a hospital population despite              
being only 5-8% of the general population. It has been demonstrated that the length of               
hospital stay and mortality is increased in patients with diabetes.  
We used a database of all inpatient capillary blood glucose testing performed in Greater              
Glasgow and Clyde Hospitals and the national database of all patients with diabetes             
(SCI-diabetes) to explore the relationship between inpatient glucose outcomes. This          
then led to a wider exploration of temporal patterns of markers of glucose control and               
clinical outcome. 
 
We analysed a large inpatient capillary blood glucose dataset to confirm that            
hypoglycaemia was common and particularly so overnight. We also inferred from           
analysis of our data that most hypoglycemia was being uncovered by routine testing             
and that there was a high chance of significant undiscovered hypoglycaemia. We then             
devised a novel metric of hypoglycaemia treatment quality (time to repeat blood            
glucose (TTR)). We used TTR as a marker of nationally agreed standards of care and               
showed poor adherence to guidelines and demonstrated that a quality improvement           
package could produce a sustained improvement in this metric. Our investigation of            
inpatient hypoglycaemia management led us to reveal that quality of hypoglycaemia           
care varied with the type of diabetes and diabetes treatment modality, with patient             
groups most at risk of harm having the least good treatment. We noticed that a highly                
cited paper was potentially overestimating the association between inpatient         
hypoglycemia and length of hospital stay as it did not take into account that the more                
measurement is made across a given distribution the more likely extreme results will be              
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found. We, therefore, used a technique which compared a mathematically modelled           
inpatient dataset with a real-world dataset. This confirmed the association between           
hypoglycaemia and length of stay remained but had been overestimated. This work            
enables more accurate health economic modelling of the impact of diabetes in hospital             
systems. 
 
During our investigation of inpatient glucose patterns and hypoglycaemia we became           
interested in whether the variability of glucose per se rather than high or low glucose               
was clinically important. We demonstrated that inpatient glucose variability is          
independently associated with long term mortality. We have also confirmed the           
association between glucose variability patients following acute stroke and renal          
replacement therapy.  
 
Our work on inpatient glucose variability led us to explore whether the variability of other               
longer-term indices of glucose control might be associated with poor outcome. We            
demonstrated an independent association between HbA1c variability and mortality in          
type 1 diabetes. We have since also shown that this association is independent and              
additive to an association between mortality and variability in visit-to-visit systolic BP.            
These data could be used to infer that the finding is not simply a marker of poor                 
treatment concordance or a chaotic lifestyle. We have also shown that variability of             
HbA1c can be reduced by attending a structured patient education course, showing that             
variability of HbA1c is also a potentially modifiable risk factor for poor outcome. 
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Dissertation 
Introduction 
 
Diabetes mellitus is a common condition which is increasing in prevalence with an             
estimated growth to 366 million diagnoses worldwide by 2030. ​(1) Interventional trials            
have clearly shown an association between prolonged poor glycaemic control and the            
development of microvascular and macrovascular complications. ​(2,3) 
 
Patients with diabetes mellitus are over represented within hospitals, accounting for up            
to 25% of an inpatient population despite accounting for only 5-8% of the general              
population. ​(4) While admission to hospital in this patient population may be due to              
complications of glycaemic control, it is often for other medical or surgical conditions. To              
ensure holistic patient management it is important to consider not only the management             
of the acute pathology leading to admission but also the management of pre-existing             
diabetes.  
 
Both inpatient and long-term mortality and length of hospital stay have been            
unequivocally demonstrated to be increased in patients with diabetes. ​(4–7) This may            
be partially attributed to suboptimal management of underlying diabetes. ​(4) Glycaemic           
control can be destabilised by the intercurrent illness itself, making the achievement of             
optimal glycaemia even more challenging in the inpatient setting. ​(6) Whilst           
hyperglycemia may play a major role in the poor outcomes seen in hospitalised patients              
with diabetes, there is increasing recognition that iatrogenic hypoglycaemia is also an            
important factor. ​(5,6,8)  
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Low blood glucose (hypoglycaemia) is recognised as a major barrier to good glucose             
control in diabetes treated with insulin and drugs that stimulate insulin secretion. ​(9,10)             
There is an international consensus that hypoglycaemia with blood glucose levels less            
than 4 mmol/l should be considered an alert value to allow people with diabetes and               
their carers to adjust insulin or consider ingesting carbohydrate and that glucose levels             
of less than 3 mmol/l would indicate serious, clinically important hypoglycaemia. ​(11)            
Clinically important hypoglycaemia triggers activation of counterregulatory hormonal        
systems and is associated with multiple negative effects, including cardiovascular          
events and death. ​(12–17)​. Whilst the presence of severe hypoglycaemia has been            
associated with up to four times the risk of cardiovascular events and mortality             
causation is controversial as hypoglycaemia may be a surrogate marker for intercurrent            
illness or frailty. ​(16) Despite the possibility that hypoglycaemia is a surrogate for the              
general clinical state the theory that hypoglycaemia causes direct harm remains           
plausible as effects can be directly observed. Studies inducing hypoglycaemia have           
shown ECG changes including ST-segment depression, T wave inversion, prolonged          
QT interval and dysrhythmias. ​(18,19) 
 
 
There has been a recognition that fluctuation in glucose levels, usually referred to as              
glucose variability, may also be an important factor in determining the risk of poor              
outcomes in diabetes over and above low and high absolute levels. The term glucose              
variability can have multiple definitions. Often it is thought of as the minute-to-minute             
and hour-to-hour changes in continuous glucose monitoring or capillary blood glucose           
testing which are used for treatment decision making ​(20)​.   
 
Several studies had shown a positive association between short term glycaemic           
variability and macrovascular and microvascular complications of diabetes. ​(7,21–23)         
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There is also evidence that high glucose variability may be linked to a reduced feeling of                
well-being and lower quality of life indices. ​(24,25)  
 
Glucose variability can also be used to describe variations of glucose control day-to-day             
or from or week-to-week.​(26,27) HbA1c is a measurement of medium term glucose and             
is a mainstay of routine management of diabetes. A reduction of HbA1c has been              
shown to improve complications and mortality in both Type 1 Diabetes Mellitus (T1DM)             
and Type 2 Diabetes Mellitus (T2DM). ​(2,3) The measurement of HbA1c is            
recommended in all patient with diabetes and locally has been measured in over 90% of               
all patient with diabetes in the preceding 15 months. ​(28,29)  
 
Much as it has with short term glucose fluctuations, the variability of long term glucose               
control as measured by changes in HbA1c has also been shown to be associated with               
adverse outcomes in diabetes. HbA1c variability is known to be positively associated            
with an increased rate of cardiovascular events in people with T1DM with a magnitude              
of the impact proposed to be is at least as high as that of mean HbA1c ​(30,31)​. It has                   
also been demonstrated that there is a positive association between visit-to-visit long            
term glucose control and a higher incidence of cardiovascular events in T2DM ​(32,33)​. 
 
The existence of an increased risk of poor outcome in people with diabetes who are in                
hospital, and the knowledge that there are patterns of glucose which seem to be              
associated with harm, suggests the potential for at least some of the excess risk being               
modifiable. It would, therefore, be of potential benefit to be able to stratify patients on               
presentation to hospital for their risk of glucose characteristics associated with poor            
outcome. This would allow the targeting of interventions such as enhanced monitoring            
and specialist advice focused on improving glucose control. 
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Likewise, a greater understanding of the importance of variability of long term glucose             
fluctuations as measured by HbA1c could allow better risk stratification and identify            
novel targets for harm reduction. 
 
My research over the past 6 years summarised in this dissertation and described in              
detail in the 9 papers accompanying this submission aim to explore these relationships.  
 
 
 
 
 
Inpatient Hypoglycaemia 
 
We analysed a large inpatient glucose dataset, of 3 345 241 CBG data points, to               
describe the trends in the timing of CBG monitoring and investigate whether these were              
appropriate based on observed patterns of hypoglycaemia. We confirmed that          
hypoglycaemia was common and occurs in 26.2% of all admissions and that it occurred              
especially frequently overnight with a peak in the risk of hypoglycaemia between 3 and              
4 am. We also inferred from the analysis by comparing ‘by the clock peaks’ of               
measurement with nadirs of measurement frequency that most hypoglycemia was being           
uncovered by routine testing and that there was a high chance of significant             
undiscovered hypoglycaemia. ​(34) This paper gives useful insight into the importance of            
hypoglycaemia and can be used to consider a more rational and targeted CBG             
monitoring regime for inpatients with diabetes.  
 
We then described a novel metric of hypoglycaemia treatment quality (time to repeat             
blood glucose (TTR)). We used TTR as a marker of nationally agreed standards of care               
and showed poor adherence to guidelines. Of 90 935 episodes of glucose <4 mmol/l              
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only 8.9 % had a repeated measure within 15 minutes. Median TTR was 80 minutes.               
TTR was shown to reduce in proportion to how low the initial measurement of CBG was                
suggesting that lower initial readings within the hypoglycaemic range were considered           
more serious. Even so, treatment was suboptimal even at very low initial CBG with              
median TTR of 22 minutes (IQR 10-47) for initial CBG of 1-1.9 mmol/l. We then               
demonstrated that a quality improvement package could produce a sustained          
improvement in this metric which persisted up to 9 months. ​(35) We believe that TTR is                
a simple real time metric which can be useful in audit and quality improvement for               
people in hospital with diabetes. 
 
Our investigation of inpatient hypoglycaemia management also led us to investigate if            
the quality of hypoglycaemia care varied with the type of diabetes and diabetes             
treatment modality. We showed that patient groups at most potential risk of harm from              
hypoglycaemia, namely those on sulphonylureas and with T2DM, have the least good            
treatment as compared to national guideline standards. ​(36) This information has been            
used to raise awareness of the importance of hypoglycaemia in high risk groups and              
was used to inform a recently published quality improvement project. ​(37)  
 
During our investigation of the importance of inpatient hypoglycaemia it had been of             
concern to us that a highly cited paper was potentially overestimating the association             
between inpatient hypoglycemia and length of hospital stay. ​(38) This paper did not take              
into account that the more measurement is made across a given distribution the more              
likely extreme results will be found. We, therefore, used a technique which compared a              
mathematically modelled inpatient dataset with a real world dataset. This confirmed the            
association between hypoglycaemia and length of stay remained but had been           
overestimated. After subtraction of the mathematical association of increased sample          
number the increased length of stay associated was lower than previously reported 0.75             
addition days to stay per day with hypoglycaemia. This work enables more accurate             
health economic modelling of the impact of diabetes in hospital systems. ​(8) 
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Cystic Fibrosis Related Diabetes (CFRD is a common complication of Cystic Fibrosis            
which differs in from other types of diabetes in its goals for management and              
complication risks. ​(39) We investigated whether there was an association between           
hypoglycaemia, hyperglycaemia or glucose variability in insulin-treated patients with         
CFRD. We demonstrated that hypoglycaemia was common and associated with an           
increased composited endpoint of readmission to hospital or death. ​(40) 
 
Glucose Variability 
 
During our investigation of inpatient glucose patterns and hypoglycaemia we became           
interested in whether the variability of inpatient glucose per se rather than high or low               
glucose was clinically important. We demonstrated that inpatient glucose variability,          
expressed as IQR, is independently associated with long term mortality at a maximum             
of 6 years follow up. This study showed that in 3755 matched pairs those in the top 50%                  
for IQR had significantly higher mortality (p=<0.01) when examined using the Cox            
proportional hazard model. ​(7) We hypothesised that this variability was likely to be a              
marker of post-discharge variability in view of the long term impact on mortality. These              
data add people with diabetes in a hospital setting to the large body of evidence               
showing an association between glucose variability and harm. No evidence yet exists to             
show that reduction of variability improves outcomes but aiming to use strategies that             
reduce variability where possible whilst awaiting further conclusive evidence could be           
considered. 
 
We also confirmed the association between glucose variability and poor outcome exists            
in various populations including people having had an acute stroke and those on renal              
replacement therapy. ​(41,42) 
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HbA1c Variability 
 
Our work on inpatient glucose variability led us to explore whether the variability of other               
longer term indices of glucose control might be associated with poor outcome. We             
investigated the association between HbA1c variability and mortality in type 1 diabetes.            
We used data from the SCI diabetes database which contains all patients with diabetes              
in Scotland. Of 6048 patients included for analysis over a period of 47 month period               
coefficient of variation (CV) above the median value hazard ratio for survival was             
increased to 1.47 (95% confidence interval 1.27-1.67)(p<0.001)  ​(43)  
 
We then further investigated the association between mortality and variability of HbA1c            
by adding visit-to -visit systolic blood pressure (SBP) as a covariable. We dichotomised             
patients above and below median values for HbA1c CV and SBP CV creating 4 cohorts               
for survival analysis. ​(44) We demonstrated that the variability of both HbA1c and visit to               
visit BP were both significantly and additively associated with mortality. These finding            
replicated those previously seen in patients with T2DM. ​(45) These data could possibly             
suggest that the finding is not simply a marker of poor treatment concordance or a               
chaotic lifestyle as this would be less likely to explain an additive impact of variability in                
SBP and HbA1c.  
 
Having shown that HbA1c is associated with mortality in T1DM we wished to investigate              
if methods used to improve overall glycaemic control might also improve variability. We             
investigated 1061 patients who had attended a Dose Adjustment for Normal Eating            
(DAFNE) course which is an evidence based structured education intervention for           
patients with T1DM. ​(46) We demonstrated that as well as reducing HbA1c variability of              
HbA1c as expressed as CV was significantly lower during the post DAFNE period than              
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prior to intervention (0.08 (IQR 0.05-0.12) reduced to 0.07 (IQR 0.05-0.10); P = 0.002),               
(47) These data give further support to the potential benefit of this structured education              
interventions on long term outcomes.. 
 
Discussion 
Inpatient Control and hypoglycaemia 
 
Patients with diabetes are over represented in the hospital inpatient population           
compared with the general population and account for up to 1 in 6 patients ​(38)​. Among                
patients with diabetes treated with insulin or sulfonylurea, the risk of hypoglycemia is             
often an important factor in preventing optimal glycemic control and treating           
hyperglycemia ​(5,6)​. In-hospital, hypoglycaemia is clearly associated with adverse         
patient outcomes such as increased length of stay and long term mortality. ​(5,6,8,38,48)  
A major issue is disentangling adverse outcomes of hypoglycemia, acute illness and            
chronic disease burden which can make it difficult to interpret inpatient data in people              
with diabetes who are admitted to hospital. Whilst our data has improved the             
understanding of the patterns of hypoglycaemia and helped quantify the potential for            
harm it is unlikely that data will ever categorically prove that inpatient hypoglycaemia is              
causative of mortality and increased resource usage. However, the observable          
physiological impact of hypoglycaemia on the cardiovascular system and the strong           
association with adverse outcomes in other settings suggests strategies to reduce           
inpatient and subsequent outpatient hypoglycemia are likely to be important. ​(15) 
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Variability 
 
The study of glucose variability is hampered by a lack of agreed definition of both the                
timescales over which variability is measured and the measurement of variability itself. 
 
It has been suggested that glucose variability can be broadly divided into short term              
(within the day or between day glucose fluctuations) and long term (between week and              
usually measured by HbA1c). ​(49,50) Increasingly measures of glucose variability are           
likely to reflect widespread availability of continuous glucose monitoring systems which           
will give the potential for the investigation of within minute variations. 
 
Various computational methods have been used to express glycaemic variability.          
Standard deviation from the mean (SD) is a simple metric of dispersion of short term               
glucose results and is often calculated directly by CBG devices. The coefficient of             
variation is calculated as percentage (SD/ mean glucose) x 100. It has the advantage of               
being simple to calculate and is adjusted for the mean. With increasing data points              
available with CGM metrics such as ​Mean Amplitude of Glycemic Excursions (​MAGE),            
which calculates mean differences from peaks to nadirs, and ​Continuous Overall Net            
Glycemic Action (​CONGA), which integrates duration and degree of glucose excursions,           
have been used and may eventually be shown to better reflect risk of poor outcome.               
(51)  
 
It is not clear why glucose variability might be harmful. Short term glucose fluctuations              
can lead to oxidative stress, endothelial dysfunction, disturbance of AKT pathways and            
cytokine release and are associated with an increased carotid intimal thickness and            
increased left ventricular mass. However, the link between glucose fluctuation and           
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oxidative stress is not been consistently demonstrated in people with diabetes.           
(21,52–55) 
 
Glucose variability is potentially important as different therapeutic options may have           
differing glycemic variability profiles. Various therapeutic agents for diabetes including          
SGLT2 inhibitors, GLP-1 analogues, DPP-4 inhibitors, CSII and the ultraslow insulin           
analogue degludec, have been shown to reduce glycemic variability. ​(56–64) 
 
It is notable that these findings relate to the effect of glucose variability over a short time                 
period and may not be relevant to longer-term glucose variability as measured by             
HbA1c. In T2DM HbA1c variability has previously been associated with an increased            
risk of developing a range of poor outcomes including depression, atrial fibrillation, heart             
failure and increased mortality. ​(65–68) Patients with T1DM and greater HbA1c           
variability may lead more chaotic lifestyles and therefore have suboptimal risk factor            
management - for example, a higher risk of developing diabetic ketoacidosis (DKA) if             
they do not engage ​(30)​. This seems plausible as people with greater HbA1c variability              
are known to have more complex medical histories, lower quality of life, low             
socioeconomic status and lack of peer support systems ​(69)​. 
 
The mechanisms linking BP variability to mortality is also unclear. Short term variability             
of blood pressure results from the interaction between intrinsic physiological,          
pathological and extrinsic environmental and behavioural factors many of which may be            
linked to poor outcomes ​(70,71)​. Longer term BP variability has been shown to be              
associated with increased mortality independently of mean BP and even when BP is             
well controlled ​(72,73)​. Longer term BP variability may represent a decreased ability to             
maintain homeostasis and this may adversely affect vascular tissues leading to           
end-organ damage ​(74,75)​. 
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The finding of a significant and additive association between SBP and HbA1c variability             
and mortality may have important clinical implications. Elevated variability may become           
important in the identification of at-risk people who may previously have been            
considered optimally managed. This may prove useful for prognostication and as an            
additional factor when evaluating the efficacy of any patient intervention. Future           
management of type 1 diabetes should perhaps focus on limiting the variability of SBP              
and HbA1c, as opposed to purely treating mean values to target. Our finding that              
DAFNE attendance can modify HbA1c variability offers hope that long term variability of             
glucose control is a tractable target for intervention. 
 
Our work has added to the understanding of how temporal patterns of glucose are              
associated with outcomes in people with diabetes in both inpatient and outpatient            
populations. This will allow better targeting of care to individuals at high risk of the               
excess morbidity and mortality seen in populations with diabetes and suggests targets            
for future therapeutic intervention. 
 
 
Future Research Directions 
 
Although the association between the variability of short and long term variability of             
glucose and adverse outcomes is established many questions remain about the nature            
of this observation.  
In the future, we plan to explore this further using linkage between inpatient CBG              
records and outpatient HbA1c records. This will allow us to explore whether short             
variability in hour-to-hour CBG is related to long term month-to-month variability in            
HbA1c. We would also like to use the increasing availability of data from flash glucose               
monitoring systems to explore the relationship between minute-to-minute glucose         
estimations and longer-term measures of variability. 
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Another area of interest moves beyond variability and looks at trajectories of measures             
of glucose control. This would explore whether particular patterns (e.g low to high or              
high to low) are the major drivers of association with variability and poor outcome.  
We have also increasing looked to machine learning techniques to allow a more             
accurate understanding of the relationship between multiple measures over time.          
Recurrent neural networks (RNN) with a ​Long short-term memory (LSTM) architecture           
classify according to sequences of values within a time series and may provide a              
valuable tool to better predict the risk of adverse outcome. We plan to use a neural                
network containing convolutional (CNN) and recurrent (RNN/LSTM) layers to treat both           
glycaemic control and other routinely recorded data (e.g BP and weight) as a             
multidimensional time series, in which the sequence of values over time and the             
interactions between values within time series is examined. 
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Fig. 2 Survival analysis time ​to first readmission or to death or over a 3.5-year follow-up                
period. Group with recorded hypoglycemia during admission 
(broken red line) was compared to the group without hypoglycemia (solid black line). HR              
Hazard ratio 
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Fig. 2. Legend: 6 year survival analysis of individuals with median CBG in upper 50% 
(≥148.5 mg/dl) (red) vs those with IQR in lower 50% (black). 3755 matched pairs, 
matched for age, duration of diabetes, duration of admission, CBG IQR and number of 
episodes of hypoglycaemia. HR for mortality (upper vs lower 50%) 0.87 ​(p<0.01)​. 
 
 
